We demonstrated for the first time that YM155 exerts potent cytotoxic activity against MM cells in G0 and G1 phase population and bortezomib resistant cells via inhibition of survivin and Mcl-1. This evidence concerns the gene MCL1 and Miyoshi myopathy.